Mireille Van Gele

Summary

Affiliation: Ghent University
Country: Belgium

Publications

  1. Van Gele M, Geusens B, Schmitt A, Aguilar L, Lambert J. Knockdown of myosin Va isoforms by RNAi as a tool to block melanosome transport in primary human melanocytes. J Invest Dermatol. 2008;128:2474-84 pubmed publisher
    ..We conclude that our siRNA-based strategy provides a previously unreported tool to block the intracellular melanosome movement in primary human melanocytes and may become an innovative drug to treat hyperpigmentation. ..
  2. Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, et al. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. J Transl Med. 2015;13:9 pubmed publisher
    ..Circulating pDC and MDSC levels should be considered in future immunoprofiling efforts as they could impact disease management. ..
  3. Desmet E, Bracke S, Forier K, Taevernier L, Stuart M, De Spiegeleer B, et al. An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: Proof-of-concept in the treatment of psoriasis. Int J Pharm. 2016;500:268-74 pubmed publisher
    ..These liposomes thus hold great potential as topical delivery system for RNAi therapeutics in the treatment of numerous skin diseases. ..
  4. Van Gele M, Dynoodt P, Lambert J. Griscelli syndrome: a model system to study vesicular trafficking. Pigment Cell Melanoma Res. 2009;22:268-82 pubmed publisher
    ..Finally, we discuss how the gathered knowledge about the RAB27A-MLPH-MYO5A tripartite complex can be translated into a possible therapeutic application to reduce (hyper)pigmentation of the skin...
  5. Van Gele M, Geusens B, Brochez L, Speeckaert R, Lambert J. Three-dimensional skin models as tools for transdermal drug delivery: challenges and limitations. Expert Opin Drug Deliv. 2011;8:705-20 pubmed publisher
    ..Whether this goal will be achieved in the near future is uncertain and will be, in the authors' opinion, a very difficult task. ..